Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in resectable NSCLC
NCT03623776Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2019
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Disease-Free Survival at 3 years. Planned start Feb 2019; status: withdrawn.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03623776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623776.